PL209317B1 - Zastosowanie propinylo-L- karnityny lub jej farmaceutycznie dopuszczalnych soli oraz jej połączenie ze znanym składnikiem aktywnym i kompozycja farmaceutyczna je zawierająca - Google Patents

Zastosowanie propinylo-L- karnityny lub jej farmaceutycznie dopuszczalnych soli oraz jej połączenie ze znanym składnikiem aktywnym i kompozycja farmaceutyczna je zawierająca

Info

Publication number: PL209317B1
Authority: PL; Poland
Prior art keywords: disease; carnitine; treatment; peyronie; propionyl
Prior art date: 2001-11-26

Application number

PL371012A

Other languages

English (en)

Polish (pl)

Other versions

PL371012A1 (en

Inventor

Aleardo Koverech

Giorgio Cavallini

Giulio Biagiotti

Original Assignee

Sigma Tau Ind Farmaceuti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-26

Filing date

2002-11-26

Publication date

2011-08-31

2002-11-26 Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti

2005-06-13 Publication of PL371012A1 publication Critical patent/PL371012A1/xx

2011-08-31 Publication of PL209317B1 publication Critical patent/PL209317B1/pl

Links

238000011282 treatment Methods 0.000 title claims abstract description 77
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 title claims abstract description 65
208000020758 Peyronie disease Diseases 0.000 title claims abstract description 62
208000004362 Penile Induration Diseases 0.000 title claims abstract description 61
239000003814 drug Substances 0.000 title claims abstract description 37
150000003839 salts Chemical class 0.000 title claims abstract description 17
238000002360 preparation method Methods 0.000 title abstract description 7
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 37
229960001722 verapamil Drugs 0.000 claims abstract description 37
239000004480 active ingredient Substances 0.000 claims abstract description 18
238000001990 intravenous administration Methods 0.000 claims abstract description 14
238000007918 intramuscular administration Methods 0.000 claims abstract description 12
238000002560 therapeutic procedure Methods 0.000 claims description 47
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 46
229960001603 tamoxifen Drugs 0.000 claims description 23
239000008194 pharmaceutical composition Substances 0.000 claims description 10
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 7
229960005294 triamcinolone Drugs 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
238000011161 development Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
238000007796 conventional method Methods 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 22
238000011443 conventional therapy Methods 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
238000000540 analysis of variance Methods 0.000 description 20
201000010099 disease Diseases 0.000 description 20
206010070653 Penile curvature Diseases 0.000 description 18
229940079593 drug Drugs 0.000 description 16
230000003993 interaction Effects 0.000 description 16
238000004458 analytical method Methods 0.000 description 13
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 12
230000001684 chronic effect Effects 0.000 description 12
208000002193 Pain Diseases 0.000 description 10
206010061818 Disease progression Diseases 0.000 description 9
210000001367 artery Anatomy 0.000 description 9
230000005750 disease progression Effects 0.000 description 9
230000004054 inflammatory process Effects 0.000 description 8
238000002604 ultrasonography Methods 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
206010016654 Fibrosis Diseases 0.000 description 6
229930003427 Vitamin E Natural products 0.000 description 6
230000004761 fibrosis Effects 0.000 description 6
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
230000008595 infiltration Effects 0.000 description 6
238000001764 infiltration Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
235000019165 vitamin E Nutrition 0.000 description 6
239000011709 vitamin E Substances 0.000 description 6
229940046009 vitamin E Drugs 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 5
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
241000776471 DPANN group Species 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
-1 colchicines Substances 0.000 description 4
239000002955 immunomodulating agent Substances 0.000 description 4
229940121354 immunomodulator Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
229930003799 tocopherol Natural products 0.000 description 4
239000011732 tocopherol Substances 0.000 description 4
235000019149 tocopherols Nutrition 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 4
230000001363 autoimmune Effects 0.000 description 3
230000001856 erectile effect Effects 0.000 description 3
230000009986 erectile function Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000003899 penis Anatomy 0.000 description 3
229940057199 potassium aminobenzoate Drugs 0.000 description 3
VLSHYHUKASKGPF-UHFFFAOYSA-M potassium;2-aminobenzoate Chemical compound [K+].NC1=CC=CC=C1C([O-])=O VLSHYHUKASKGPF-UHFFFAOYSA-M 0.000 description 3
238000011160 research Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
229940005505 tamoxifen 20 mg Drugs 0.000 description 3
229960002117 triamcinolone acetonide Drugs 0.000 description 3
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
206010061876 Obstruction Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
210000003195 fascia Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
GJTJQSPLLQWKMB-SECBINFHSA-N (3R)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical class C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-SECBINFHSA-N 0.000 description 1
KTFMPDDJYRFWQE-DDWIOCJRSA-N (3r)-3-propanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride Chemical compound [Cl-].CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C KTFMPDDJYRFWQE-DDWIOCJRSA-N 0.000 description 1
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
WCBVOPMSONYWEB-UHFFFAOYSA-N 2-aminoacetyl chloride Chemical compound NCC(Cl)=O WCBVOPMSONYWEB-UHFFFAOYSA-N 0.000 description 1
XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 description 1
WTSLUSVMTIYTKZ-UHFFFAOYSA-N 2-aminoethanesulfonic acid;hydrochloride Chemical compound Cl.NCCS(O)(=O)=O WTSLUSVMTIYTKZ-UHFFFAOYSA-N 0.000 description 1
QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
GJTJQSPLLQWKMB-UHFFFAOYSA-N 3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical class C(C)(=O)C(O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-UHFFFAOYSA-N 0.000 description 1
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
102000052603 Chaperonins Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
108700003861 Dominant Genes Proteins 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
206010024870 Loss of libido Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000404883 Pisa Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
229960001009 acetylcarnitine Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
229960000711 alprostadil Drugs 0.000 description 1
230000006497 arterial abnormality Effects 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229960004203 carnitine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000021735 chronic enteritis Diseases 0.000 description 1
230000007881 chronic fibrosis Effects 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
238000000556 factor analysis Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
239000007926 intracavernous injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960005336 magnesium citrate Drugs 0.000 description 1
235000002538 magnesium citrate Nutrition 0.000 description 1
239000004337 magnesium citrate Substances 0.000 description 1
229940095060 magnesium tartrate Drugs 0.000 description 1
MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 description 1
QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 description 1
YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
238000012148 non-surgical treatment Methods 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
230000037390 scarring Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000002633 shock therapy Methods 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940104261 taurate Drugs 0.000 description 1
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229940066528 trichloroacetate Drugs 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
208000037997 venous disease Diseases 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL371012A 2001-11-26 2002-11-26 Zastosowanie propinylo-L- karnityny lub jej farmaceutycznie dopuszczalnych soli oraz jej połączenie ze znanym składnikiem aktywnym i kompozycja farmaceutyczna je zawierająca PL209317B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001RM000695A ITRM20010695A1 (it)	2001-11-26	2001-11-26	Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del

Publications (2)

Publication Number	Publication Date
PL371012A1 PL371012A1 (en)	2005-06-13
PL209317B1 true PL209317B1 (pl)	2011-08-31

Family

ID=11455896

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371012A PL209317B1 (pl)	2001-11-26	2002-11-26	Zastosowanie propinylo-L- karnityny lub jej farmaceutycznie dopuszczalnych soli oraz jej połączenie ze znanym składnikiem aktywnym i kompozycja farmaceutyczna je zawierająca

Country Status (17)

Country	Link
US (1)	US20050038044A1 (de)
EP (1)	EP1448184B1 (de)
JP (1)	JP4370168B2 (de)
KR (1)	KR100923139B1 (de)
AT (1)	ATE323481T1 (de)
AU (1)	AU2002358991A1 (de)
CA (1)	CA2466135C (de)
CY (1)	CY1105347T1 (de)
DE (1)	DE60210804T2 (de)
DK (1)	DK1448184T3 (de)
ES (1)	ES2261772T3 (de)
HU (1)	HUP0402118A3 (de)
IT (1)	ITRM20010695A1 (de)
MX (1)	MXPA04004900A (de)
PL (1)	PL209317B1 (de)
PT (1)	PT1448184E (de)
WO (1)	WO2003045373A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8465413B2 (en)	2010-11-25	2013-06-18	Coloplast A/S	Method of treating Peyronie's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2658307C2 (de) *	1976-12-22	1979-03-15	Klinge Pharma Gmbh & Co, 8000 Muenchen	Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1983001782A1 (en) *	1981-11-18	1983-05-26	Merk, Werner	Fat refining
US5038633A (en) *	1989-09-28	1991-08-13	Kabushiki Kaisha Kobe Seiko Sho	Transmission for mini shovel car
IT1283967B1 (it) *	1996-03-29	1998-05-07	Sigma Tau Ind Farmaceuti	Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US6069175A (en) *	1996-11-15	2000-05-30	Pfizer Inc.	Estrogen agonist/antagonists treatment of atherosclerosis
IT1290600B1 (it) *	1997-04-30	1998-12-10	Sigma Tau Ind Farmaceuti	Composizioni solide atte alla somministrazione orale comprendenti l-carnitina e alcanoil l-carnitine magnesio fumarato
IT1302858B1 (it) *	1998-11-11	2000-10-10	Sigma Tau Ind Farmaceuti	Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento avente attivita' antitumorale.

2001
- 2001-11-26 IT IT2001RM000695A patent/ITRM20010695A1/it unknown
2002
- 2002-11-26 KR KR1020047007881A patent/KR100923139B1/ko not_active Expired - Fee Related
- 2002-11-26 DK DK02793337T patent/DK1448184T3/da active
- 2002-11-26 DE DE60210804T patent/DE60210804T2/de not_active Expired - Lifetime
- 2002-11-26 MX MXPA04004900A patent/MXPA04004900A/es active IP Right Grant
- 2002-11-26 PL PL371012A patent/PL209317B1/pl unknown
- 2002-11-26 US US10/496,659 patent/US20050038044A1/en not_active Abandoned
- 2002-11-26 ES ES02793337T patent/ES2261772T3/es not_active Expired - Lifetime
- 2002-11-26 JP JP2003546875A patent/JP4370168B2/ja not_active Expired - Fee Related
- 2002-11-26 AT AT02793337T patent/ATE323481T1/de active
- 2002-11-26 PT PT02793337T patent/PT1448184E/pt unknown
- 2002-11-26 HU HU0402118A patent/HUP0402118A3/hu unknown
- 2002-11-26 AU AU2002358991A patent/AU2002358991A1/en not_active Abandoned
- 2002-11-26 EP EP02793337A patent/EP1448184B1/de not_active Expired - Lifetime
- 2002-11-26 WO PCT/IT2002/000745 patent/WO2003045373A1/en not_active Ceased
- 2002-11-26 CA CA2466135A patent/CA2466135C/en not_active Expired - Fee Related
2006
- 2006-05-30 CY CY20061100685T patent/CY1105347T1/el unknown

Also Published As

Publication number	Publication date
JP4370168B2 (ja)	2009-11-25
MXPA04004900A (es)	2004-08-02
EP1448184B1 (de)	2006-04-19
HUP0402118A2 (hu)	2005-02-28
AU2002358991A1 (en)	2003-06-10
HUP0402118A3 (en)	2012-09-28
US20050038044A1 (en)	2005-02-17
CA2466135A1 (en)	2003-06-05
KR100923139B1 (ko)	2009-10-23
ATE323481T1 (de)	2006-05-15
PL371012A1 (en)	2005-06-13
WO2003045373A1 (en)	2003-06-05
DE60210804D1 (de)	2006-05-24
ITRM20010695A1 (it)	2003-05-26
DK1448184T3 (da)	2006-08-21
EP1448184A1 (de)	2004-08-25
ES2261772T3 (es)	2006-11-16
CY1105347T1 (el)	2010-03-03
KR20040058316A (ko)	2004-07-03
PT1448184E (pt)	2006-07-31
DE60210804T2 (de)	2006-10-19
JP2005511638A (ja)	2005-04-28
CA2466135C (en)	2011-05-31
ITRM20010695A0 (it)	2001-11-26

Publication	Publication Date	Title
Neff et al.	2002	Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease
JP2002541097A (ja)	2002-12-03	線維筋痛症及び関連症状の治療におけるフルピルチン
WO2003092682A1 (en)	2003-11-13	Zonisamide use in obesity and eating disorders
KR20140121475A (ko)	2014-10-15	특발성 염증성 근질환의 예방 또는 치료제
US20200188405A1 (en)	2020-06-18	Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
KR20060007034A (ko)	2006-01-23	혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도
HK119994A (en)	1994-11-11	Method of treatment for interstitial cystitis
US9968626B2 (en)	2018-05-15	Method for treating obesity
US20110117070A1 (en)	2011-05-19	Compositions and methods for treating headache
JP7344422B2 (ja)	2023-09-14	糖尿病予防・治療用の医薬品組成物及びその用途
JPH03227921A (ja)	1991-10-08	ケロイド治療剤
AU5100300A (en)	2000-12-05	Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation
JP2004536076A (ja)	2004-12-02	Ｐ−ｇｐインヒビターおよび抗癲癇薬を含んでなる組合せ剤
EP1448184B1 (de)	2006-04-19	Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit
US20040014681A1 (en)	2004-01-22	Method for treating dermatoses and tissue damage
JP2002515035A (ja)	2002-05-21	アミノステロール化合物の治療学的使用
RU2457834C1 (ru)	2012-08-10	Способ лечения метаболического синдрома
Palmer et al.	1951	Triethanolamine Trinitrate—Clinical Trial
US20060128738A1 (en)	2006-06-15	Treatment of interstitial cystitis using cannabinoid analogs
EP2482658B1 (de)	2015-07-01	Verfahren und zusammensetzungen zur behandlung des raynaud-syndroms
HRP20020201A2 (en)	2003-06-30	Pharmaceutical compositions for treating psoriasis
JP2024505246A (ja)	2024-02-05	神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
CN119907669A (zh)	2025-04-29	用于治疗肝损伤的硝唑尼特
DE102004040630A1 (de)	2006-03-09	Kombinationstherapie mit Procain